Literature DB >> 12127871

Farnesyltransferase inhibitors: promises and realities.

Adrienne D Cox1, Channing J Der.   

Abstract

Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias, gliomas and even non-small-cell lung cancers, especially when administered in combination with taxanes. It is possible that the critical target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12127871     DOI： 10.1016/s1471-4892(02)00181-9

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  29 in total

1.  RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development.

Authors:  Irit Adini; Isaac Rabinovitz; Jing Fang Sun; George C Prendergast; Laura E Benjamin
Journal:  Genes Dev       Date:  2003-11-01       Impact factor: 11.361

2.  Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo.

Authors:  Shehab A Ismail; Yong-Xiang Chen; Alexandra Rusinova; Anchal Chandra; Martin Bierbaum; Lothar Gremer; Gemma Triola; Herbert Waldmann; Philippe I H Bastiaens; Alfred Wittinghofer
Journal:  Nat Chem Biol       Date:  2011-10-16       Impact factor: 15.040

Review 3.  Unraveling the mechanism of the farnesyltransferase enzyme.

Authors:  Sérgio Filipe Sousa; Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  J Biol Inorg Chem       Date:  2004-12-21       Impact factor: 3.358

4.  Rho2 is a target of the farnesyltransferase Cpp1 and acts upstream of Pmk1 mitogen-activated protein kinase signaling in fission yeast.

Authors:  Yan Ma; Takayoshi Kuno; Ayako Kita; Yuta Asayama; Reiko Sugiura
Journal:  Mol Biol Cell       Date:  2006-09-27       Impact factor: 4.138

5.  Effects of pharmacologic inhibition of protein geranylgeranyltransferase type I on aqueous humor outflow through the trabecular meshwork.

Authors:  P Vasantha Rao; Yuri K Peterson; Toshihiro Inoue; Patrick J Casey
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-03       Impact factor: 4.799

6.  Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones.

Authors:  Stephen B Porter; Emily R Hildebrandt; Sarah R Breevoort; David Z Mokry; Timothy M Dore; Walter K Schmidt
Journal:  Biochim Biophys Acta       Date:  2007-03-20

7.  Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Authors:  Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

8.  Identification, functional expression and enzymic analysis of two distinct CaaX proteases from Caenorhabditis elegans.

Authors:  Juan Cadiñanos; Walter K Schmidt; Antonio Fueyo; Ignacio Varela; Carlos López-Otín; José M P Freije
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

9.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

10.  Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Authors:  Helen Court; Marc Amoyel; Michael Hackman; Kyoung Eun Lee; Ruliang Xu; George Miller; Dafna Bar-Sagi; Erika A Bach; Martin O Bergö; Mark R Philips
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.